The cancer therapeutics developer, backed by Novo and Immunocore, raised the cash less than a year after closing a nine-figure series A round.
Adaptimmune Therapeutics, a UK-based biopharmaceutical company backed by pharmaceutical firm Novo and biotechnology company Immunocore, raised $191.3m yesterday when it priced an initial public offering on Nasdaq at $17.00 per share.
The company issued 11.25 million shares, and the IPO’s underwriters have the 30-day option to buy almost 1.7 million additional shares, which would push the size of the offering up to approximately $220m.
Founded in 2008, Adaptimmune is developing immunotherapy products to treat cancer based on its T-cell…
